Please enable JavaScript to continue using this application.

Compare $DMRA vs $REPL | Chartloom

Compare

$DMRA vs $REPL

Damora Therapeutics Inc · Replimune Group Inc

DMRA

Damora Therapeutics Inc

REPL

Replimune Group Inc

Compare $DMRA vs $REPL

Comparing Damora Therapeutics Inc and Replimune Group Inc

DMRADamora Therapeutics Inc

REPLReplimune Group Inc

DMRADamora Therapeutics Inc

Market cap

$1.30B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-17.4%

52W performance

-17.4%

FCF yield

-3.4%

REPLReplimune Group Inc

Market cap

$1.13B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

40.24x

Rev growth (TTM)

—

YTD performance

50.8%

52W performance

188.6%

FCF yield

-24.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

DMRA

REPL

Detailed metrics comparison

DMRA

Damora Therapeutics Inc

REPL

Replimune Group Inc

Market Cap

DMRA$1.30B

REPL$1.13B

Enterprise Value

DMRA$757M

REPL$1.05B

Price

DMRA$21.08

REPL$13.42

P/E Ratio

DMRAN/A

REPLN/A

P/S Ratio

DMRA0.00x

REPL0.00x

EV/Sales

DMRA0.00x

REPL0.00x

EV/EBITDA

DMRA0.00x

REPL0.00x

P/B Ratio

DMRA2.47x

REPL11.66x

P/FCF Ratio

DMRAN/A

REPLN/A

EV/FCF

DMRA-17.00x

REPL-3.75x

PEG Ratio

DMRAN/A

REPLN/A

Forward P/E (NTM)

DMRAN/A

REPLN/A

Forward P/S (NTM)

DMRAN/A

REPL40.24x

Revenue (TTM)

DMRA$0

REPL$0

Revenue Growth (YoY)

DMRAN/A

REPLN/A

Forward Rev Growth

DMRA346.9%

REPL397.3%

Gross Margin (TTM)

DMRA0.0%

REPL0.0%

Operating Margin (TTM)

DMRA0.0%

REPL0.0%

EBITDA Margin (TTM)

DMRA0.0%

REPL0.0%

Net Margin (TTM)

DMRA0.0%

REPL0.0%

FCF Margin (TTM)

DMRAN/A

REPLN/A

Net Income (TTM)

DMRA$-265M

REPL$-297M

FCF (TTM)

DMRA$-45M

REPL$-281M

EPS (TTM)

DMRA-$4.34

REPL-$3.07

ROE (TTM)

DMRA-8306.0%

REPL-15932.0%

ROA (TTM)

DMRA-7849.0%

REPL-9084.0%

ROIC (TTM)

DMRA-8306.0%

REPL-10727.0%

Cash

DMRA$541M

REPL$185M

Debt

DMRA$0

REPL$109M

Net Cash/Debt

DMRA$541M

REPL$77M

Current Ratio (TTM)

DMRA19.73x

REPL5.23x

Quick Ratio (TTM)

DMRA19.70x

REPL5.09x

Debt/Equity (TTM)

DMRA0.00x

REPL1.03x

Debt/Assets (TTM)

DMRA0.0%

REPL0.0%

Interest Coverage (TTM)

DMRAN/A

REPLN/A

Net Debt/EBITDA (TTM)

DMRA0.00x

REPL0.00x

Beta

DMRA-4.05

REPL0.97

52W Performance

DMRA-17.4%

REPL188.6%

YTD Performance

DMRA-17.4%

REPL50.8%

% from 52W High

DMRA-39.6%

REPL-17.8%

% from 52W Low

DMRA27.8%

REPL794.7%

Asset Turnover (TTM)

DMRA0.00x

REPL0.00x

FCF Yield (TTM)

DMRA-3.4%

REPL-24.9%

Earnings Yield (TTM)

DMRA-20.4%

REPL-26.3%

Dividend Yield (TTM)

DMRAN/A

REPLN/A

Rule of 40

DMRA0.0

REPL0.0

EV/GP/RG

DMRAN/A

REPLN/A

Ticker research

View DMRA research View REPL research

Metric	DMRA Damora Therapeutics Inc	REPL Replimune Group Inc
Market & Valuation
Market Cap	$1.30B	$1.13B
Enterprise Value	$757M	$1.05B
Price	$21.08	$13.42
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.47x	11.66x
P/FCF Ratio	N/A	N/A
EV/FCF	-17.00x	-3.75x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	40.24x
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	346.9%	397.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-265M	$-297M
FCF (TTM)	$-45M	$-281M
EPS (TTM)	-$4.34	-$3.07
ROE (TTM)	-8306.0%	-15932.0%
ROA (TTM)	-7849.0%	-9084.0%
ROIC (TTM)	-8306.0%	-10727.0%
Financial Health
Cash	$541M	$185M
Debt	$0	$109M
Net Cash/Debt	$541M	$77M
Current Ratio (TTM)	19.73x	5.23x
Quick Ratio (TTM)	19.70x	5.09x
Debt/Equity (TTM)	0.00x	1.03x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-4.05	0.97
52W Performance	-17.4%	188.6%
YTD Performance	-17.4%	50.8%
% from 52W High	-39.6%	-17.8%
% from 52W Low	27.8%	794.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-3.4%	-24.9%
Earnings Yield (TTM)	-20.4%	-26.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View DMRA research	View REPL research

Valuation

P/S Ratio

DMRA

0.00x

REPL

0.00x

EV/FCF

DMRA

-17.00x

REPL

-3.75x

Growth & revenue

Forward Revenue Growth

REPL

397.3%

DMRA

346.9%

Profitability & performance

Gross Margin

DMRA

0.0%

REPL

0.0%

ROE

DMRA

-8306.0%

REPL

-15932.0%

FCF Yield %

DMRA

-3.4%

REPL

-24.9%

52-Week Performance

REPL

188.6%

DMRA

-17.4%

Detailed metrics comparison

DMRA

Damora Therapeutics Inc

REPL

Replimune Group Inc

Market Cap

DMRA$1.30B

REPL$1.13B

Enterprise Value

DMRA$757M

REPL$1.05B

Price

DMRA$21.08

REPL$13.42

P/E Ratio

DMRAN/A

REPLN/A

P/S Ratio

DMRA0.00x

REPL0.00x

EV/Sales

DMRA0.00x

REPL0.00x

EV/EBITDA

DMRA0.00x

REPL0.00x

P/B Ratio

DMRA2.47x

REPL11.66x

P/FCF Ratio

DMRAN/A

REPLN/A

EV/FCF

DMRA-17.00x

REPL-3.75x

PEG Ratio

DMRAN/A

REPLN/A

Forward P/E (NTM)

DMRAN/A

REPLN/A

Forward P/S (NTM)

DMRAN/A

REPL40.24x

Revenue (TTM)

DMRA$0

REPL$0

Revenue Growth (YoY)

DMRAN/A

REPLN/A

Forward Rev Growth

DMRA346.9%

REPL397.3%

Gross Margin (TTM)

DMRA0.0%

REPL0.0%

Operating Margin (TTM)

DMRA0.0%

REPL0.0%

EBITDA Margin (TTM)

DMRA0.0%

REPL0.0%

Net Margin (TTM)

DMRA0.0%

REPL0.0%

FCF Margin (TTM)

DMRAN/A

REPLN/A

Net Income (TTM)

DMRA$-265M

REPL$-297M

FCF (TTM)

DMRA$-45M

REPL$-281M

EPS (TTM)

DMRA-$4.34

REPL-$3.07

ROE (TTM)

DMRA-8306.0%

REPL-15932.0%

ROA (TTM)

DMRA-7849.0%

REPL-9084.0%

ROIC (TTM)

DMRA-8306.0%

REPL-10727.0%

Cash

DMRA$541M

REPL$185M

Debt

DMRA$0

REPL$109M

Net Cash/Debt

DMRA$541M

REPL$77M

Current Ratio (TTM)

DMRA19.73x

REPL5.23x

Quick Ratio (TTM)

DMRA19.70x

REPL5.09x

Debt/Equity (TTM)

DMRA0.00x

REPL1.03x

Debt/Assets (TTM)

DMRA0.0%

REPL0.0%

Interest Coverage (TTM)

DMRAN/A

REPLN/A

Net Debt/EBITDA (TTM)

DMRA0.00x

REPL0.00x

Beta

DMRA-4.05

REPL0.97

52W Performance

DMRA-17.4%

REPL188.6%

YTD Performance

DMRA-17.4%

REPL50.8%

% from 52W High

DMRA-39.6%

REPL-17.8%

% from 52W Low

DMRA27.8%

REPL794.7%

Asset Turnover (TTM)

DMRA0.00x

REPL0.00x

FCF Yield (TTM)

DMRA-3.4%

REPL-24.9%

Earnings Yield (TTM)

DMRA-20.4%

REPL-26.3%

Dividend Yield (TTM)

DMRAN/A

REPLN/A

Rule of 40

DMRA0.0

REPL0.0

EV/GP/RG

DMRAN/A

REPLN/A

Ticker research

View DMRA research View REPL research

Metric	DMRA Damora Therapeutics Inc	REPL Replimune Group Inc
Market & Valuation
Market Cap	$1.30B	$1.13B
Enterprise Value	$757M	$1.05B
Price	$21.08	$13.42
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.47x	11.66x
P/FCF Ratio	N/A	N/A
EV/FCF	-17.00x	-3.75x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	40.24x
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	346.9%	397.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-265M	$-297M
FCF (TTM)	$-45M	$-281M
EPS (TTM)	-$4.34	-$3.07
ROE (TTM)	-8306.0%	-15932.0%
ROA (TTM)	-7849.0%	-9084.0%
ROIC (TTM)	-8306.0%	-10727.0%
Financial Health
Cash	$541M	$185M
Debt	$0	$109M
Net Cash/Debt	$541M	$77M
Current Ratio (TTM)	19.73x	5.23x
Quick Ratio (TTM)	19.70x	5.09x
Debt/Equity (TTM)	0.00x	1.03x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-4.05	0.97
52W Performance	-17.4%	188.6%
YTD Performance	-17.4%	50.8%
% from 52W High	-39.6%	-17.8%
% from 52W Low	27.8%	794.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-3.4%	-24.9%
Earnings Yield (TTM)	-20.4%	-26.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View DMRA research	View REPL research